Efficacy of the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) to reduce the need for X-ray in pregnant patients with COVID-19

dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637en_US
dc.authoridCem Dane / 0000-0002-7498-2153en_US
dc.authorscopusidMehmet Hilmi Doğu / 55212747300en_US
dc.authorscopusidCem Dane / 57678682300en_US
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017
dc.authorwosidCem Dane / A-1285-2011
dc.contributor.authorDoğu, Sevilay Yavuz
dc.contributor.authorSerin, İstemi
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorGüleroğlu, Filiz Yarşılıkal
dc.contributor.authorDane, Cem
dc.date.accessioned2022-06-03T14:13:58Z
dc.date.available2022-06-03T14:13:58Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPregnancy carries a significant risk for coronavirus disease-2019 (COVID-19) due to natural immunosuppression. A previous study from our center has shown that the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) can be used in the early diagnosis of COVID-19 and predicting mortality. Based on this, we aimed to determine the effect of LLR on early detection of critical pregnant women and mortality in COVID-19. The data of 145 patients who were admitted to our hospital between March and December 2020; diagnosed with COVID-19 and hospitalized, were retrospectively analyzed. The median gestation period was 31 weeks (range: 5-41), 30.3% (n: 44) gave birth and 68.3% (n: 99) were pregnant. Median LLR was 0.13 (range: 0.04-0.70). The rate of cough (47% vs. 22.8%; p=0.003) was found to be high in patients with LLR>0.13. The patients were divided into subgroups. The proportion of patients without active complaints was higher in the Q1, followed by the Q4. The proportion of patients with an initial complaint of cough increased as LLR from Q1 to Q4, the distribution of other complaints did not differ between the quartiles. The higher rate of cough in the group with high LLR indicates that it may be an important indicator of lung involvement during pregnancy. The highest rate of non-treatment follow-up in the lowest LLR group proved that the LLR value at the time of diagnosis can be used as an important clinical marker in pregnant women. © 2022 De Gruyter. All rights reserved.en_US
dc.identifier.citationDogu, S. Y., Serin, I., Dogu, M. H., Guleroglu, F. Y., & Dane, C. (2022). Efficacy of the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) to reduce the need for X-ray in pregnant patients with COVID-19. Journal of Perinatal Medicine, doi:10.1515/jpm-2021-0341en_US
dc.identifier.doi10.1515/jpm-2021-0341en_US
dc.identifier.issn0300-5577en_US
dc.identifier.scopus2-s2.0-85129904929en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1515/jpm-2021-0341
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2794
dc.identifier.wosWOS:000788841200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorDoğu, Mehmet Hilmi
dc.institutionauthorDane, Cem
dc.language.isoenen_US
dc.publisherDe Gruyter Openen_US
dc.relation.ispartofJournal of Perinatal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectLDH/lymphocyte Ratio (LLR)en_US
dc.subjectPregnancyen_US
dc.subjectPrognosisen_US
dc.titleEfficacy of the lactate dehydrogenase (LDH)/lymphocyte ratio (LLR) to reduce the need for X-ray in pregnant patients with COVID-19en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10.1515_jpm-2021-0341.pdf
Boyut:
260.72 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: